Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound

Novo Nordisk's CagriSema failed to demonstrate non-inferior weight loss versus Eli Lilly's Zepbound in the REDEFINE-4 (84-week) Phase III readout and showed weaker glucose control in REIMAGINE 2/3, undermining its role as a successor ahead of semaglutide patent expiry in 2031. Deutsche Bank cut its rating to 'hold' and slashed its price target 31% to DKK275, JPMorgan moved to 'neutral' with a DKK250 target and reduced CagriSema forecasts 40–63% through 2027–2030 (with EPS cuts of 2–17% across JPMorgan's five‑year window), while Citi trimmed its target to DKK309 and noted CagriSema represented ~18% of its DCF (peak sales $6.5bn obesity, $5.5bn diabetes). The share price closed at DKK251.40, down ~21% over the week (15% on Monday), signaling materially higher downside risk to Novo's long-term earnings profile and investor positioning.

Analysis

Market structure: Eli Lilly (LLY) is the clear direct beneficiary — Zepbound’s superiority should accelerate Lilly’s share gains in obesity/diabetes and allow continued premium pricing; expect NVO share erosion versus LLY of 5–15 percentage points in key markets over 12–24 months. Contract manufacturers, dual‑chamber device suppliers and Novo’s CagriSema-specific supply chain are losers given higher complexity and lower commercial upside, reducing NVO’s manufacturing margin optionality post-2031 semaglutide cliff.

Risk assessment: Immediate risk is a volatility spike and 10–30% downside in NVO within days as positioning de‑risks (already -21% week); short-term (3–12 months) risks include payer-driven price depression and weaker uptake of follow-ons, while the long-term (to 2031+) risk is failure to replace semaglutide revenue — Citi’s model tie (CagriSema = 18% of DCF; halving reduces NPV ~9%) is a useful sensitivity. Tail risks: regulatory setbacks, manufacturing failures for dual‑chamber device, or competitor pricing concessions triggering classwide reimbursement cuts.

Trade implications: Expect elevated IV for NVO options for 3–9 months; use defined‑risk put spreads to play downside and consider pair trades long LLY vs short NVO to capture asymmetric share reallocation. Cross‑asset: NVO credit spreads may widen modestly (10–30bps); short EUR/DKK exposure is lower priority but monitor DKK if large outflows persist; pharma ETFs should underweight GLP‑1 concentrated names.

Contrarian/valuation: Consensus assumes CagriSema was sole replacement — that may be overpessimistic. If NVO falls >30% (DKK~175–180) or forward EPS cuts exceed 25%, the stock could become a tactical deep‑value buy given scale, other pipeline assets and potential buybacks/M&A over 12–24 months; historical parallel: Pfizer post‑Lipitor loss where diversification and buybacks restored value over years.

Key Decisions for Investors

• Establish a defined‑risk bearish position: buy 6–9 month NVO put spread (buy ATM puts, sell 30–40% OTM) sized to 2–3% of portfolio to profit if NVO falls to DKK~180–200 within 3–9 months; roll or unwind if implied vol >50% or price drops below DKK175.
• Implement a pair trade: go long LLY (1.5–3% of portfolio) and short NVO (1.5–3%) for a 6–12 month horizon to capture market share reallocation; hedge sector beta with a small position in XLV or IHI if needed.
• Trim long exposure to GLP‑1‑concentrated pharma by 2–4% and redeploy into medtech/oncology ETFs (e.g., IHI) or specific names with non‑GLP pipelines; target redeploy within 5 trading days to capture repricing.
• If NVO closes below DKK200 on a 3‑day average, scale bearish allocations by 50% and add staggered 12‑month put calendars; conversely, consider accumulating a long position if NVO trades <DKK175 and consensus EPS cuts exceed 25%, holding 12–24 months for mean reversion.
• Monitor catalysts aggressively: NVO Q1 results and any new REIMAGINE/Amycretin readouts over the next 60–180 days — set alerts for press releases and clinical data; reprice positions within 48 hours of any positive data or major guidance change.